TACR3 and breast cancer: In our a priori and post-hoc analyses, we have demonstrated that administration of an oral NK3R antagonist (MLE4901) to menopausal women does not change serum FSH or estradiol concentration, despite dramatic reductions in hot flashes.(11) This is particularly reassuring for women with a contraindication to conventional hormone therapy, such as those with a history of hormonally sensitive breast cancer or thromboembolism, those on estrogen deprivation therapy, and/or those at risk of deleterious bone loss.